Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Jun Yin, Jingnan Yuan, Yunjin Li, Yong Fang, Ruoxi Wang, Heng Jiao, Han Tang, Shaoyuan Zhang, Siyun Lin, Feng Su, Jianmin Gu, Tian Jiang, Dong Lin, Zhiliang Huang, Chaoxiang Du, Kui Wu, Lijie Tan, Qing Zhou, Jun Yin, Jingnan Yuan, Yunjin Li, Yong Fang, Ruoxi Wang, Heng Jiao, Han Tang, Shaoyuan Zhang, Siyun Lin, Feng Su, Jianmin Gu, Tian Jiang, Dong Lin, Zhiliang Huang, Chaoxiang Du, Kui Wu, Lijie Tan, Qing Zhou
Abstract
Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable ESCC. Patients received two neoadjuvant doses of adebrelimab followed by surgery. The primary endpoints were safety and feasibility; secondary endpoints included pathologic complete response (pCR) and OS. Our data showed the primary endpoints of safety and feasibility had been met. Common treatment-related adverse events were anorexia (32%) and fatigue (16%), without grade 3 or more adverse events. Of the 30 patients enrolled in the trial, 25 underwent successful resection without surgery delay and 24% had major pathologic responses including a pCR rate of 8%. The 2-year OS was 92%. Responsive patients had an immune-enriched tumor microenvironment phenotype, whereas nonresponsive patients had greater infiltration of cancer-associated fibroblasts at baseline. Clonotypic dynamics of pre-existing intratumoral T cells was a hallmark of responsive patients. These findings provide a rational for neoadjuvant anti-PD-L1 monotherapy as a therapeutic strategy for patients with resectable ESCC. ClinicalTrials.gov identifier: NCT04215471 .
Conflict of interest statement
The authors declare no competing interests.
© 2023. The Author(s).
Figures
References
- Eyck BM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J. Clin. Oncol. 2021;39:1995–2004. doi: 10.1200/JCO.20.03614.
- Tang H, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann. Oncol. 2023;34:163–172. doi: 10.1016/j.annonc.2022.10.508.
- Yang H, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156:721–729. doi: 10.1001/jamasurg.2021.2373.
- Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 2021;384:1191–1203. doi: 10.1056/NEJMoa2032125.
- Ho WJ, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat. Cancer. 2021;2:891–903. doi: 10.1038/s43018-021-00234-4.
- Menzies AM, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Nat. Med. 2021;27:301–309. doi: 10.1038/s41591-020-01188-3.
- Forde PM, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 2018;378:1976–1986. doi: 10.1056/NEJMoa1716078.
- Chalabi M, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 2020;26:566–576. doi: 10.1038/s41591-020-0805-8.
- Gao J, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 2020;26:1845–1851. doi: 10.1038/s41591-020-1086-y.
- Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 2020;26:475–484. doi: 10.1038/s41591-020-0829-0.
- Xu J, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24:483–495. doi: 10.1016/S1470-2045(23)00108-0.
- Kojima T, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 2020;38:4138–4148. doi: 10.1200/JCO.20.01888.
- Salas-Benito D, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11:1353–1367. doi: 10.1158/-20-1312.
- Wang H, Li S, Liu T, Chen J, Dang J. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: a systematic review and meta-analysis. Front. Immunol. 2022;13:998620. doi: 10.3389/fimmu.2022.998620.
- van den Ende T, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT) Clin. Cancer Res. 2021;27:3351–3359. doi: 10.1158/1078-0432.CCR-20-4443.
- Mu L, et al. SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: a multicentre, phase 2 study. Thorac. Cancer. 2021;12:1373–1381. doi: 10.1111/1759-7714.13913.
- Wang J, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739–747. doi: 10.1016/S1470-2045(22)00224-8.
- Yan W, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II to III NSCLCs: an open-label, multicenter, phase 1b trial. J. Thorac. Oncol. 2023;18:194–203. doi: 10.1016/j.jtho.2022.09.222.
- Matsuda S, et al. Distribution of residual disease and recurrence patterns in pathological responders after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann. Surg. 2022;276:298–304. doi: 10.1097/SLA.0000000000004436.
- Matsuda, S. et al. Nationwide validation study of the prognostic significance of stratification using pathological stage and response to neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann. Surg.10.1097/SLA.0000000000005701 (2022).
- McGranahan N, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–1271.e1211. doi: 10.1016/j.cell.2017.10.001.
- Zhang X, et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat. Commun. 2021;12:5291. doi: 10.1038/s41467-021-25539-x.
- Bagaev A, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39:845–865.e847. doi: 10.1016/j.ccell.2021.04.014.
- Peranzoni E, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc. Natl Acad. Sci. USA. 2018;115:e4041–e4050. doi: 10.1073/pnas.1720948115.
- Xu J, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) Nat. Commun. 2022;13:857. doi: 10.1038/s41467-022-28408-3.
- Yost KE, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 2019;25:1251–1259. doi: 10.1038/s41591-019-0522-3.
- Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 2022;19:775–790. doi: 10.1038/s41571-022-00689-z.
- Voabil P, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 2021;27:1250–1261. doi: 10.1038/s41591-021-01398-3.
- Chaft JE, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat. Med. 2022;28:2155–2161. doi: 10.1038/s41591-022-01962-5.
- Doki Y, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 2022;386:449–462. doi: 10.1056/NEJMoa2111380.
- Lu Z, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. doi: 10.1136/bmj-2021-068714.
- Wang ZX, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40:277–288 e273. doi: 10.1016/j.ccell.2022.02.007.
- Luo H, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916–925. doi: 10.1001/jama.2021.12836.
- Sun JM, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–771. doi: 10.1016/S0140-6736(21)01234-4.
- Liu J, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J. Immunother. Cancer. 2022;10:e004291. doi: 10.1136/jitc-2021-004291.
- Li C, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1) Eur. J. Cancer. 2021;144:232–241. doi: 10.1016/j.ejca.2020.11.039.
- Huang B, et al. Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma. J. Gastrointest. Oncol. 2021;12:2013–2021. doi: 10.21037/jgo-21-610.
- Sjoquist KM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–692. doi: 10.1016/S1470-2045(11)70142-5.
- Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182. doi: 10.1126/science.aax0182.
- Zhang B, et al. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer. Front. Immunol. 2023;14:1066527. doi: 10.3389/fimmu.2023.1066527.
- Zhang G, et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. eBioMedicine. 2023;90:104515. doi: 10.1016/j.ebiom.2023.104515.
- Chen X, et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. J. Immunother. Cancer. 2023;11:e005830. doi: 10.1136/jitc-2022-005830.
- Zhang Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578–1593.e1578. doi: 10.1016/j.ccell.2021.09.010.
- Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 2022;21:529–540. doi: 10.1038/s41573-022-00493-5.
- Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43:523–545. doi: 10.1016/j.it.2022.04.010.
- Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer. 2023;23:295–316. doi: 10.1038/s41568-023-00560-y.
- Liu B, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer. 2022;3:108–121. doi: 10.1038/s43018-021-00292-8.
- Im SJ, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417–421. doi: 10.1038/nature19330.
- Bentham R, et al. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature. 2021;597:555–560. doi: 10.1038/s41586-021-03894-5.
- Loiseau N, et al. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning. BMC Med. Res. Methodol. 2022;22:335. doi: 10.1186/s12874-022-01799-z.
Source: PubMed